LENZ Therapeutics
LENZ Therapeutics
LENZ
NASDAQ
24.10
USD
-2.03%
About
LENZ Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. Its product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively.
LNZ100 and LNZ101 are under clinical evaluation in the registration-enabling Phase III CLARITY trials as potential therapies for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 99.1K |
| Three Month Average Volume | 3.5M |
| High Low | |
| Fifty-Two Week High | 25.77 USD |
| Fifty-Two Week Low | 9.51321 USD |
| Fifty-Two Week High Date | 01 Aug 2024 |
| Fifty-Two Week Low Date | 15 Nov 2023 |
| Price and Volume | |
| Current Price | 23.39 USD |
| Beta | -100,000 |
| Relative Price Change | |
| Four Week Relative Price Change | -7.83% |
| Thirteen Week Relative Price Change | 42.93% |
| Twenty-Six Week Relative Price Change | 32.59% |
| Fifty-Two Week Relative Price Change | 77.66% |
| Year-to-Date Relative Price Change | 59.29% |
| Price Change | |
| One Day Price Change | 5.84% |
| Thirteen Week Price Change | 52.98% |
| Twenty-Six Week Price Change | 45.79% |
| Five Day Price Change | 3.96% |
| Fifty-Two Week Price Change | 122.62% |
| Year-to-Date Price Change | 88.63% |
| Month-to-Date Price Change | -5.80% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 22.1528 USD |
| Book Value Per Share (Most Recent Quarter) | 7.46436 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 22.1528 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 7.46436 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -4.94001 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -15.30364 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -9.45304 USD |
| Normalized (Last Fiscal Year) | -7.67312 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -15.30364 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -9.45304 USD |
| Including Extraordinary Items (Last Fiscal Year) | -15.30364 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -9.45304 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 22.23449 USD |
| Cash Per Share (Most Recent Quarter) | 7.58781 USD |
| Cash Flow Per Share (Last Fiscal Year) | -15.00812 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -6.10199 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -8.55391 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 94.13% |
| EPS Change (Trailing Twelve Months) | 41.07% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 4 |
| Price to Tangible Book (Most Recent Quarter) | 3 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -196,112,000 |
| Net Debt (Last Fiscal Year) | -184,259,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | 3 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 39 |
| Current Ratio (Most Recent Quarter) | 23 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -100,863,000 |
| Free Cash Flow (Trailing Twelve Months) | -100,006,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -48.85% |
| Return on Assets (Trailing Twelve Months) | -29.53% |
| Return on Assets (5 Year) | -99,999.99% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -51.95% |
| Return on Equity (Trailing Twelve Months) | -34.67% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -50.62% |
| Return on Investment (Trailing Twelve Months) | -30.84% |
| Return on Investment (5 Year) | -99,999.99% |